Grifols, S.A.
GRFSHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Grifols, S.A. focuses on Drug Manufacturers - General services and products. Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and. The $4.95B market capitalization puts GRFS squarely in mid-cap range for its industry. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.
Market Cap
$4.95B
Beta
1.18
P/E (TTM)
10.54
P/E (Fwd)
5.03
EPS (TTM)
$0.69
EPS (Fwd)
$1.44
ROE
6.1%
ROA
4.2%
Cash
$702.0M
Total Debt
$9.67B
Free CF
$887.5M
52W Change
-26.9%
Annual Financials
Cash vs Debt
The company holds $702.0M in cash, though total debt stands at $9.67B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $887.5M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 6.1%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.2% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $6.06B (2022) to $7.52B (2025), reflecting a 24% increase over the period.
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Grifols, S.A. and its sector.